C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Invests $448,000 in Illumina, Inc. (NASDAQ:ILMN)

C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the 4th quarter, Holdings Channel reports. The fund bought 3,352 shares of the life sciences company’s stock, valued at approximately $448,000.

Other hedge funds also recently bought and sold shares of the company. Sanctuary Advisors LLC increased its stake in shares of Illumina by 2.8% during the fourth quarter. Sanctuary Advisors LLC now owns 23,424 shares of the life sciences company’s stock valued at $3,116,000 after buying an additional 646 shares during the period. Strategic Financial Concepts LLC bought a new stake in Illumina in the fourth quarter valued at $1,464,000. Allworth Financial LP increased its position in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company’s stock valued at $1,001,000 after purchasing an additional 6,263 shares during the period. Principal Securities Inc. raised its holdings in Illumina by 38.8% in the 4th quarter. Principal Securities Inc. now owns 1,728 shares of the life sciences company’s stock worth $231,000 after purchasing an additional 483 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC lifted its position in shares of Illumina by 8.3% in the 4th quarter. Chevy Chase Trust Holdings LLC now owns 526,414 shares of the life sciences company’s stock worth $70,345,000 after purchasing an additional 40,219 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Trading Up 1.9 %

Shares of Illumina stock opened at $102.98 on Thursday. Illumina, Inc. has a fifty-two week low of $99.33 and a fifty-two week high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The company has a market capitalization of $16.31 billion, a P/E ratio of -13.41, a P/E/G ratio of 1.66 and a beta of 1.10. The company has a fifty day moving average of $129.96 and a 200 day moving average of $134.41.

Illumina (NASDAQ:ILMN) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, sell-side analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on ILMN. JPMorgan Chase & Co. increased their price target on shares of Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. Royal Bank of Canada lowered their target price on Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Canaccord Genuity Group reduced their price target on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. Robert W. Baird boosted their target price on shares of Illumina from $124.00 to $139.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Finally, Barclays downgraded shares of Illumina from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $130.00 to $100.00 in a research report on Monday, February 10th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.